Author(s): Chim CS, Ma SY, Au WY, Choy C, Lie AK,
Abstract Share this page
Abstract Nasal natural killer (NK) cell lymphoma is rare, so that its optimal therapy, long-term outcome, and prognostic factors are unclear. Data on 52 men and 15 women with well-characterized nasal NK cell lymphomas were analyzed retrospectively to define the impact of primary therapy on remission and long-term outcome and the validity of the International Prognostic Index (IPI). Most (84\%) had stage I/II disease with an IPI score of 1 or less (52\%). Seven patients received radiotherapy only; 47 patients received anthracycline-containing chemotherapy plus consolidation radiotherapy; and 12 patients received nonanthracycline-containing chemotherapy plus radiotherapy. The overall complete remission (CR) rate was 64.2\%; the 20-year overall survival (OS) and disease-free survival (DFS) rates were 37.1\% and 33.5\%, respectively. Front-line radiotherapy was apparently better than chemotherapy for CR (100\% versus 59\%, P =.04) and OS (83.3\% versus 32.0\%, P =.03). Relapses occurred in 4 radiotherapy-treated (all local) and 14 chemotherapy-treated patients (9 local, 4 systemic). Among these, 5 late relapses (4 local, 1 systemic) occurred at 170 months (range, 92-348 months) from CR. The IPI score was of prognostic significance for the whole group (IPI or= 2 for 20-year OS: 57.4\% versus 27.6\%, P = 0.012), as well as for patients treated with chemotherapy/radiotherapy (IPI or= 2 for CR: 76.7\% versus 35.7\%, P =.017; and 10-year OS: 63.8\% versus 26.8\%, P =.003).
This article was published in Blood and referenced in Journal of Clinical Case Reports